These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32497363)

  • 1. Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.
    Smith MP; Rupon J; Wali Y; Rimawi H; Korth-Bradley J; Smith L; Rendo P
    Haemophilia; 2020 Sep; 26(5):e232-e235. PubMed ID: 32497363
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
    Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
    Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
    Steele MR; Nagel K; Chan AK
    Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
    Korth-Bradley J; Rupon J; Plotka A; Charnigo R; Rendo P
    Clin Transl Sci; 2018 May; 11(3):283-288. PubMed ID: 29575770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: Data from REF.IT Registry.
    Zanon E; Pasca S; Pollio B; Santagostino E; Linari S; Tagliaferri A; Santoro C; Rocino A; Marino R; Aru B; Borchiellini A; Siragusa S; Coppola A
    Haemophilia; 2019 Nov; 25(6):1003-1010. PubMed ID: 31603594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
    Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
    Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.
    Ozelo M; Misgav M; Abdul Karim F; Lentz SR; Martin-Salces M; Matytsina I; Saugstrup T; Santagostino E
    Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 13. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
    Lentz SR; Cerqueira M; Janic D; Kempton C; Matytsina I; Misgav M; Oldenburg J; Ozelo M; Recht M; Rosholm A; Savic A; Suzuki T; Tiede A; Santagostino E
    Haemophilia; 2016 Sep; 22(5):e445-9. PubMed ID: 27291066
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilia care: from paediatrics to geriatrics. Introductory note.
    Oldenburg J; Salek SZ
    Haemophilia; 2009 Jan; 15 Suppl 1():1. PubMed ID: 19125933
    [No Abstract]   [Full Text] [Related]  

  • 17. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
    Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
    Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
    Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
    Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home management of hemophilia A.
    Van Eys J
    J Tenn Med Assoc; 1971 May; 64(5):407-10. PubMed ID: 5091669
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.